Tilak Mandadi - 30 Nov 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role: EVP, Chief DDAT Officer
Signature: /s/ Tilak Mandadi
Issuer symbol: CVS
Transactions as of: 30 Nov 2024
Net transactions value: +$2,999,981
Form type: 4
Filing time: 03 Dec 2024, 17:13:49 UTC
Previous filing: 03 Sep 2024
Next filing: 03 Apr 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CVS	Common Stock (RSU)	Award	$2,999,981	+50,125	+101%	$59.85	99,747	30 Nov 2024	Direct	F1
holding	CVS	Common Stock						40,414	30 Nov 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CVS	Stock Option						96,496	30 Nov 2024	Common Stock	96,496	$74.31	Direct	F2
holding	CVS	Stock Option						67,920	30 Nov 2024	Common Stock	67,920	$79.56	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 11/30/2025.
F2	Option becomes exercisable in four equal annual installments, commencing 4/1/2024.
F3	Option becomes exercisable in four equal annual installments, commencing 4/1/2025.